Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.69
-$0.04(-5.93%)
At close: 4:00 PM EDT
$0.69
-$0.04(-5.93%)
Day’s Range― - ―
52-Week Range$0.50 - $2.14
Previous Close$0.65
Volume24.70K
Average Volume (3M)90.44K
Market Cap
$32.67M
Enterprise Value$52.35
Total Cash (Recent Filing)$39.54M
Total Debt (Recent Filing)$56.39M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding44,766,148
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.67Price Target Upside141.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$86.71M
Bulls Say, Bears Say
Bulls Say
Launch Of Fully Resorbable OviTex LTRIntroducing a fully resorbable hernia portfolio is a structural product expansion that increases addressable market and aligns with surgeon preference for resorbable solutions. Durable differentiation supports long-term adoption, pricing preservation, and expanded procedure use across open, laparoscopic and robotic approaches.
Fully Staffed U.S. Commercial OrganizationA completed commercial build provides sustained account coverage and scale. As new reps reach six-month breakeven, unit economics should improve, enabling more predictable revenue per territory and durable revenue growth if salesforce productivity and retention stay on track.
Unit Growth And International ExpansionConsistent unit growth and a strong European breakout indicate product-market fit beyond the U.S., diversifying revenue drivers. International procurement wins (NHS selection) and rising procedure adoption create a multi-geography revenue base that supports durable top-line expansion and lowers single-market dependence.
Bears Say
Deteriorated Capitalization / Negative EquityNegative equity plus meaningful debt reduces financial flexibility, elevates refinancing and covenant risks, and increases dependence on external capital. Over the medium term this raises the probability of dilutive financings or constrained investment in commercial execution if operating losses persist.
Persistent Cash Burn And Negative FCFOngoing negative operating and free cash flow means the business is not yet self-funding; sustained cash burn forces reliance on external funding. Even with improving trends, continued deficits constrain strategic optionality and make execution on commercial plans contingent on successful capital access or rapid revenue inflection.
Listing And Execution Risk (Nasdaq Notice)A minimum bid deficiency notice creates structural listing uncertainty that can distract management, limit financing avenues, and pressure investor confidence. Combined with execution-dependent guidance (rep maturation, contract timing), this elevates the operational and capital-execution risk profile over the coming months.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $2.14 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $32.67M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Aug 10, 2026 which is in 7 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on May 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.17.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,766,148 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.67 (141.55% Upside)
$1.67 (141.55% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.53%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed constructive early progress with multiple meaningful positives: fully staffed U.S. commercial team, a major product launch (OviTex LTR), strong international performance (+41% in Europe), 16% unit growth, growing clinical evidence, and a board refresh to support scaling. These highlights were balanced against near-term financial pressures — modest 3% revenue growth in Q1, gross margin compression, a slightly wider net loss driven by higher interest expense, PRS utilization volatility due to concentration risk, and execution/timing risks tied to rep maturation and contract timing. Management expects an inflection in productivity as new hires reach the 6-month mark and reiterated at least 8% full-year revenue growth, signaling confidence in a stronger back half. Overall, the narrative is of early validation and building momentum, but with clear execution risks to realize the projected ramp.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$1.67
▲(141.55% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
20.80% Insiders
4.91% Mutual Funds
3.23% Other Institutional Investors
67.62% Public Companies and
Individual Investors